One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics (NASDAQ: GPCR), was a victim of a ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the ...

Spire Wealth Management bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,949 shares of the company’s ...

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...

In this article, we discuss the 10 best rebound stocks to invest in now.

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...